Washington, D.C. (March 16, 2018) – The Biotechnology Innovation Organization (BIO) commends Governor Matt Mead for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines, with appropriate communication to patients and physicians.Governor Mead signed Senate File 75 this week, following broad bipartisan support in both the Wyoming Senate and House. The policies outlined in the bill align with BIO’s principles on biologic substitution and garnered our support. BIO is grateful to Senator Fred Baldwin for his sponsorship of the bill, and to the legislature and Governor Mead for their leadership on this issue.“Senate File 75 enjoys the support of physicians across Wyoming and the country, patient groups, and both innovator biologic and biosimilar manufacturing companies. This bill includes provisions to ensure appropriate communication on all biologic medicines dispensed, in order to maintain a consistent and complete medical record,” said Jim Greenwood, BIO’s President and Chief Executive Officer. "By signing this bill into law, Governor Mead has added Wyoming to the list of states that allow retail pharmacies to substitute interchangeable biologic medicines."While the U.S. Food and Drug Administration (FDA) oversees approval of biologic medicines and designation of interchangeability, policies governing whether one product may be substituted in place of a doctor's prescription and whether a pharmacist must inform patients and doctors are covered by state law. Senate File 75 seeks to properly preserve patient access to accurate prescription information, maintain incentives for innovation and promote a competitive market for biologic therapies. BIO supports full communication in the substitution process, as patients and their physicians should know what biologic medicine the patient receives from the pharmacy.While the FDA has approved biosimilar products for sale in the U.S., the…

BIO submitted written testimony to the U.S. House Ways and Means Subcommittee on Tax Policy, for the hearing “Post Tax Reform Evaluation of Recently Expired Tax Provisions,” asking the committee to provide a seamless multi-year extension of the Second Generation Biofuel Producer Tax Credit; the Special Depreciation Allowance for Second Generation Biofuel Plant Property; the Biodiesel and Renewable Diesel Fuels Credit; and the Alternative Fuel Vehicle Refueling Property, which Congress recently extended retroactively for 2017 but are currently expired.

BIO regrets signing of misleading drug pricing and reporting bill by Oregon Governor Brown, as it will fail to provide patients the lower drug costs they were promised

Washington, D.C. (March 13, 2018) - Each year, the Biotechnology Innovation Organization (BIO) presents the Rosalind Franklin Award for Leadership in Industrial Biotechnology to an outstanding woman in the industrial biotechnology sector who has made significant contributions to the advancement of the biobased economy and biotech innovation. BIO is now accepting nominations for the 2018 Rosalind Franklin Award. The award will be presented at the 2018 World Congress on Industrial Biotechnology in Philadelphia at the Pennsylvania Convention Center from July 16-19, 2018. The deadline to submit nominations is March 28, 2018. 

Washington, D.C. (March 12, 2018) – The International Council of Biotech Associations (ICBA) today announced the launch of internationalbiotech.org, a new website to support the organization’s mission of growing and connecting the innovative biotechnology industry worldwide.The website unites publicly available resources of ICBA members, providing a virtual library of materials ranging from economic and employment data to issue specific whitepapers. The site’s interactive map demonstrates the distribution of the biotechnology industry around the world, enabling users to easily contrast key economic data markers, including the percent of GDP spent by businesses and governments on research and development.“The increasingly global biotechnology industry provides breakthrough products and technologies that combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes,” said Andrew Casey, Chair of the ICBA and President & CEO, BIOTECanada. “The challenges and opportunities faced by the biotechnology industry cross borders. This website demonstrates the steps our industry is taking to better coordinate, organize and face these issues around the world together.”About ICBAThe International Council of Biotechnology Associations (ICBA) is a coalition of non-profit, national biotechnology trade associations formed to promote public understanding of, and to advocate for, public policies that support the growth of the innovative biotechnology industries. The ICBA represents the global voice of the industry in international fora with the goal of promoting continued innovation in the human health, agriculture, and industrial and environmental sectors. ###

BIO voiced its opposition to the GREENER Fuels Act, introduced by Sen. Tom Udall (D-NM) and Rep. Peter Welch (D-VT), because it would revise the Renewable Fuel Standard (RFS) in way that will chill investment in advanced biofuel.

Washington, DC (March 1, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding the introduction by Senator Charles Grassley of S. 2453, the Ensuring the Value of the 340B Program Act of 2018: